enow.com Web Search

  1. Ads

    related to: inhalers without steroids for copd patients treatment near me cost

Search results

  1. Results from the WOW.Com Content Network
  2. GSK to cap out-of-pocket inhaler costs in US - AOL

    www.aol.com/news/gsk-cap-pocket-inhaler-costs...

    The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

  3. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

    www.aol.com/news/astrazeneca-cap-us-pocket-costs...

    Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1. ... pulmonary disease (COPD), AstraZeneca ...

  4. AstraZeneca capping COPD, asthma medications at $35 a month - AOL

    www.aol.com/news/astrazeneca-capping-copd-asthma...

    For premium support please call: 800-290-4726 more ways to reach us

  5. Dry-powder inhaler - Wikipedia

    en.wikipedia.org/wiki/Dry-powder_inhaler

    A dry-powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin) have also been used in the treatment of diabetes mellitus. [1]

  6. Pulmonary drug delivery - Wikipedia

    en.wikipedia.org/wiki/Pulmonary_drug_delivery

    Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...

  7. Aclidinium bromide - Wikipedia

    en.wikipedia.org/wiki/Aclidinium_bromide

    Aclidinium bromide is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States in July 2012 [3] as a maintenance treatment for chronic obstructive pulmonary disease (COPD). [4] Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. [5]

  1. Ads

    related to: inhalers without steroids for copd patients treatment near me cost